The question that comes to mind when one considers the risks of a clinical trial is, “Why would anyone agree to participate?” Interviews with trial volunteers and their family members make clear that often it is the appeal of discovering something new and unknown.
Clara C. Hildebrandt, MD and Jonathan M. Marron, MD, MPH
Gene editing with CRISPR/Cas9 raises concerns about equitable access to therapies that could limit research participation by minority group members. These concerns can be addressed through public education, transparency, and stakeholder partnerships.
AMA J Ethics. 2018;20(9):E826-833. doi:
10.1001/amajethics.2018.826.
Emergency medical consultations share with other emergencies the need for prompt action, potentially without information or tools ordinarily available.
AMA J Ethics. 2016;18(5):479-484. doi:
10.1001/journalofethics.2016.18.5.ecas1-1605.
Does a patient’s request not to have a diagnosis included in her health record undermine a clinician’s capacity to provide clinically and ethically appropriate treatment?
AMA J Ethics. 2016;18(6):579-586. doi:
10.1001/journalofethics.2016.18.6.ecas2-1606.
Dr Lisa Fuller joins Ethics Talk to discuss her article: “How Should Organizations and Clinicians Help Marginalized Patients Manage Loneliness as a Harm of Climate Change?”